Jennifer M. Specht

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade

Shivani Srivastava, Scott N. Furlan, Carla A. Jaeger-Ruckstuhl et al. · Cancer Cell · 2020 · 334 citations · Full text

Life Sciences, Immunology, Oncology +17

Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases

Jennifer M. Specht, Gang Wang, My T. et al. · The Journal of Experimental Medicine · 1997 · 306 citations · Full text

Life Sciences, Immunology, Oncology +17

Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer

Joyce O’Shaughnessy, Lee Schwartzberg, Michael A. Danso et al. · Journal of Clinical Oncology · 2014 · 305 citations · Full text

Medicine, Oncology, Pharmacology +15

Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer

Lisa K. Dunnwald, Julie R. Gralow, Georgiana K. Ellis et al. · Journal of Clinical Oncology · 2008 · 157 citations · Full text

Medicine, Nuclear Medicine, Oncology +17